| Drug Class | Sponsor and/or Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Antibody, Broadly Neutralizing | National Institute of Allergy and Infectious Diseases (NIAID) | SAR441236 | A tri-specific broadly neutralizing antibody against HIV-1 | Phase 1 | Recruiting | |
| Antibody, Monoclonal | Rockefeller University | 10-1074 | Highly neutralizing monoclonal antibody against HIV-1 | Phase 2 | Active, Not Recruiting |
542606
|
| Antibody, Monoclonal | Rockefeller University | 3BNC117 -LS | Highly neutralizing monoclonal antibody against HIV-1 | Phase 2 | Active, Not Recruiting | |
| Antibody, Monoclonal | Columbia University | 10E8.4 Mab | Bispecific antibody | Phase 1 | Active, Not Recruiting | |
| Antibody, Monoclonal | AbbVie | Budigalimab | ABBV-181 | Phase 1 | Completed | |
| Antibody, Monoclonal | National Institute of Allergy and Infectious Diseases (NIAID) | Cemiplimab | Anti-PD-1 antibody | Phase 1/2 | Terminated | |
| Antibody, Monoclonal | Ottawa Hospital Research Institute | Entyvio™ | Vedolizumab; a humanized monoclonal antibody | Phase 2 | Recruiting | |
| Antibody, Monoclonal | National Institutes of Health Clinical Center (CC) | Keytruda™ | Pembrolizumab, IgG4 kappa monoclonal anti-PD-1 antibody | Phase 1 | Recruiting | |
| Antibody, Monoclonal | MacroGenics; National Institute of Allergy and Infectious Diseases (NIAID) | MGD014 | JNJ-64052781; HIV-1 x CD3 bispecific DART molecule | Phase 1 | Completed | |
| Antibody, Monoclonal | National Institute of Allergy and Infectious Diseases (NIAID) | VRC07-523LS | VRC07-523-LS; VRC-HIVMAB075-00-AB | Phase 2 | Recruiting |
599294
|
| Antibody, Monoclonal | United BioPharma | UB-421 | Monoclonal antibody; mAb dB4C7 | Phase 3 | Not Yet Recruiting | |
| Antibody, Monoclonal | TaiMed Biologics Inc.; Westat | TMB-365 | Anti-CD4 recombinant humanized monoclonal antibody | Phase 1 | Completed | |
| Antibody, Monoclonal | St George's, University of London | P2G12 | Neutralizing monoclonal antibody against HIV-1 | Phase 1 | Unknown |
578224
|
| Capsid Inhibitor | Gilead Sciences | Sunlenca™ | Lenacapavir; GS-6207 | FDA Approved December 2022 | |
599611
|
| Combination | ViiV Healthcare | Triumeq™ PD | Abacavir sulfate & Dolutegravir sodium & Lamivudine; ABC & DTG & 3TC | FDA Approved March 2022 | | |
| Combination | ANRS, Emerging Infectious Diseases | Tivicay™ & Rezolsta™ | Dolutegravir & Darunavir & Cobicistat | Phase 3 | Completed | |
| Combination | Rockefeller University | 10-1074-LS-J & 3BNC117-LS-J | Two broadly neutralizing monoclonal antibodies | Phase 1/2 | Active, Not Recruiting | |
| Combination | National Institute of Allergy and Infectious Diseases (NIAID) | PGT121 & PGDM1400 & 10-1074 & VRC07-523LS | Four monoclonal antibodies | Phase 1 | Completed | |
| Combination | National Institute of Allergy and Infectious Diseases (NIAID) | PGT121.414.LS & VRC07-523LS | Two monoclonal antibodies | Phase 1 | Active, Not Recruiting | |
| Entry and/or Fusion Inhibitor | Sangamo BioSciences | SB-728-T | | Phase 1/2 | Completed | |
| Entry and/or Fusion Inhibitor | ViiV Healthcare; GlaxoSmithKline | Temsavir | BMS-626529 | Phase 2 | Completed |
345401
|
| Entry and/or Fusion Inhibitor | National Institute of Allergy and Infectious Diseases (NIAID); Genzyme | Mavorixafor | AMD-070; AMD-11070; X4P-001 | Phase 1/2 | Completed |
495149
|
| Entry and/or Fusion Inhibitor | Pfizer | PF-00232798 | | Phase 2 | Completed |
582838
|
| Entry and/or Fusion Inhibitor | CytoDyn, Inc. | Leronlimab | PRO-140; PA14 | Phase 2/3 | Active, Not Recruiting |
088103
|
| Entry and/or Fusion Inhibitor | Incyte Corporation | INCB-009471 | INCB-9471 | Phase 2 | Completed |
503495
|
| Entry and/or Fusion Inhibitor | Navigen, Inc.; Covance; National Institute of Allergy and Infectious Diseases (NIAID) | CPT31 | Cholesterol-PIE12-trimer | Phase 1 | Completed |
596858
|
| Entry and/or Fusion Inhibitor | Tobira Therapeutics | Cenicriviroc | TBR-652; TAK-652 | Phase 2 | Completed |
224423
|
| Entry and/or Fusion Inhibitor | Frontier Biotechnologies Co., Ltd | Aikening™ | ABT; FB006M; Albuvirtide | Phase 3 | Completed |
531982
|
| Entry and/or Fusion Inhibitor | Rapid Pharmaceuticals | Adaptavir | RAP101; monomeric d-Ala-peptide T-amide (mDAPTA) | Phase 2 | Unknown |
052004
|
| HIV Latency Reversing Agent | Immune System Regulation AB | Triptorelin | Gonadotropin releasing hormone agonist | Phase 2 | Unknown | |
| HIV Latency Reversing Agent; Histone Deacetylase (HDAC) Inhibitor | Shenzhen Chipscreen Biosciences Co., Ltd | Epidaza™ | CS-055, Chidamide, HBI-8000 | Phase 1/2 | Completed | |
| HIV Latency Reversing Agent; Histone Deacetylase (HDAC) Inhibitor | McGill University Health Center; Abbott Labs | Depakote™ | Valproic acid, Divalproex sodium, Valproate(VPA) | Phase 1/2 | Completed |
057177
|
| HIV Latency Reversing Agent; Histone Deacetylase (HDAC) Inhibitor | Massachusetts General Hospital; Novartis | Farydak™ | Panobinostat | Phase 1/2 | Active, Not Recruiting |
580714
|
| HIV Latency Reversing Agent; Histone Deacetylase (HDAC) Inhibitor | Aarhus University Hospital | Istodax™ | Romidepsin | Phase 2 | Active, Not Recruiting |
565088
|
| HIV Latency Reversing Agent; Histone Deacetylase (HDAC) Inhibitor | Imperial College London; Merck | Zolinza™ | Vorinostat; MK-0683, Suberoylanilide Hydroxamic Acid (SAHA), CCRIS 8456 | Phase 2 | Active, Not Recruiting |
186714
|
| HIV Latency Reversing Agent; Toll-Like Receptor 3 (TLR-3) Agonist | National Institute of Allergy and Infectious Diseases (NIAID); Oncovir, Inc. | Hiltonol™ | Poly-ICLC | Phase 1/2 | Completed |
187148
|
| Immunomodulator | University of Aarhus | Lefitolimod | MGN-1703 | Phase 2 | Active, Not Recruiting | |
| Immunomodulator | University of Minnesota | IL-15 | Interleukin 15 | Phase 2 | Recruiting |
398478
|
| Immunomodulator | Georgetown University; Amgen | Enbrel™ | Etanercept; p75 TNFR-Fc fusion protein | Phase 1 | Completed | |
| Immunomodulator | Fred Hutchinson Cancer Research Center | CellCept™; Myfortic™ | Mycophenolate Mofetil; MMF | Phase 2 | Completed |
059828
|
| Immunomodulator | The Research Council of Norway | Arcoxia™ | Etoricoxib | Phase 2 | Completed | |
| Immunomodulator | National Institute of Allergy and Infectious Diseases (NIAID) | Arava™ | Leflunomide | Phase 1 | Completed |
009747
|
| Immunomodulator | Merck | PEG-Intron™; Pegasys™ | PEG IFN alpha-2a | Phase 3 | Completed | |
| Immunomodulator | National Institute of Allergy and Infectious Diseases (NIAID); Pfizer (Wyeth) | Ammonium Trichlorotellurate; Ossirene | AS-101 | Phase 1 | Completed |
000042
|
| Integrase Inhibitor | Boehringer Ingelheim | BI-224436 | | Phase 1 | Withdrawn |
566575
|
| Janus Kinase Inhibitor | National Institute of Allergy and Infectious Diseases (NIAID) | Ruxolitinib | | Phase 2 | Completed |
564288
|
| Maturation Inhibitor | GlaxoSmithKline | GSK2838232 | | Phase 2 | Completed | |
| Maturation Inhibitor | ViiV Healthcare | GSK3739937 | | Phase 1 | Completed | |
| Maturation Inhibitor | ViiV Healthcare | GSK3640254 | | Phase 2 | Completed | |
| Microbicide | Centre for the AIDS Programme of Research in South Africa; Gilead Sciences | Tenofovir gel | GS-1278; PMPA gel, Apropovir, TFV | Phase 3 | Completed |
021800
|
| Microbicide | CONRAD; Uniroyal; Crompton Corp; Biosyn | UC781 | Thiocarboxanilide | Phase 1 | Completed |
029940
|
| Microbicide | Starpharma Pty Ltd | VivaGel™ | SPL-7013 gel | Phase 1/2 | Completed |
223863
|
| Microbicide | National Institute of Allergy and Infectious Diseases (NIAID) ; Population Council | PC-1005 | MIV-150 & Zinc Acetate & Carrageenan Gel | Phase 1 | Completed |
543486
|
| Microbicide | GlaxoSmithKline | GSK706769 | | Phase 1 | Completed | |
| Microbicide | Population Council | Griffithsin Gel | | Phase 1 | Completed |
336134
|
| Microbicide | Johns Hopkins University | DuoGel | IQP-0528 | Phase 1 | Completed |
104929
|
| Microbicide | International Partnership for Microbicides, Inc. | DS003 | BMS793 | Phase 1 | Completed |
335384
|
| Microbicide | Reprotect, Inc. | BufferGel™ | Carbomer 974P, Carbopol 974P, Carbopol polymer | Phase 2 | Completed |
180064
|
| Microbicide | Myrexis, Inc.; Panacos Pharmaceuticals | Bevirimat | BVM, PA-457, MPC-4326, DSB, YK-FH312 | Phase 2 | Completed |
028530
|
| NNRTI | Viriom | Elpida™ | Elsulfavirine; VM-1500A (long acting injection) | Phase 2/3 | Completed | |
| NNRTI | Kainos Medicine Inc. | KM-023 | | Phase 1 | Completed | |
| NNRTI | St. Stephen's AIDS Trust | TMC278-LA | A long-acting formulation of Janssen's Rilpivirine | Phase 2 | Completed |
169030
|
| NRTI | RFS Pharma; Biochem Pharma; Triangle Pharmaceuticals; Gilead Sciences | Amdoxovir | DAPD | Phase 2 | Completed |
005431
|
| NRTI | Merck | Islatravir | EFdA; MK-8591 | Phase 3 | Active, Not Recruiting |
343654
|
| NRTI | Merck | MK-8504 | Prodrug of tenofovir | Phase 1 | Completed | |
| NRTI | Merck | MK-8583 | Prodrug of tenofovir | Phase 1 | Completed | |
| NRTI | GlaxoSmithKline; Pharmasset, Inc. | Racivir | RCV; (+/-)FTC, 5-FSddC, LDS-022, PSI 5004 | Phase 2 | Completed |
005245
|
| NRTI | Gilead Sciences | Vemlidy™ | Tenofovir Alafenamide (prodrug of tenofovir); GS-7340 | Phase 3 | Completed |
046774
|
| NRTI | Achillion Pharmaceuticals; Vion Pharmaceuticals | Elvucitabine | ACH-126443; beta-L-Fd4C | Phase 2 | Completed |
060327
|
| Protease Inhibitor | Concert Pharmaceuticals | C-10299 | Isotopic Analog of Atazanavir (ATV) | Phase 1 | Completed | |
| Protease Inhibitor | Tibotec Pharmaceuticals | TMC-310911 | | Phase 2 | Completed |
483146
|
| Protease Inhibitor | Concert Pharmaceuticals | C-10297 | Isotopic Analog of Atazanavir (ATV) | Phase 1 | Completed | |
| Protease Inhibitor | Concert Pharmaceuticals | C-10276 | Isotopic Analog of Atazanavir (ATV) | Phase 1 | Completed | |
| Proteasome Inhibitor | Mayo Clinic | Ninlaro™ | Ixazomib | Phase 1/2 | Completed |
589853
|
| Rev Inhibitor | Abivax SA | ABX464 | | Phase 1/2 | Completed |
516635
|
| Toll-Like Receptor 7 (TLR-7) Agonist | Gilead Sciences | Vesatolimod | GS-9620 | Phase 2 | Active, Not Recruiting |
574840
|
| Unidentified | AbbVie | ABBV-382 | | Phase 1 | Recruiting | |
| Unidentified | Shanxi Kangbao Biological Product Co., Ltd.; Chinese Academy of Medical Sciences; Institute of Pathogen Biology | Lipovirtide Injection | | Phase 1 | Recruiting | |
| Unidentified | Merck | MK-4250 | | Phase 1 | Completed | |
| Unidentified | Merck | MK-8527 | | Phase 1 | Completed | |
| Unidentified | Merck | MK-8558 | | Phase 1 | Completed | |